Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment — Christian Rolfo (2020) | RDL Network
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
Article 2020 en
Authors
CR
Christian Rolfo
NI
Nicolás Isambert
AI
Antoîne Italiano
Abstract
1 min read
Patients with MiHI or MoHI had no clinically significant changes in exposure to olaparib compared with patients with NHF. The safety profile of olaparib did not differ from a clinically relevant extent between cohorts. No olaparib tablet or capsule dose reductions are required for patients with MiHI or MoHI.
Stan B. Kaye, Steinar Aamdal, Richard D. Jones, Gilles Freyer, Éric Pujade-Lauraine, Elisabeth G.E. de Vries, Jorge Barriuso, Shahneen Sandhu, Daniel S.W. Tan, V Hartog, Bart C. Kuenen, Rita Ruijter, Gunnar B. Kristensen, Marta Nyakas, Sophie Barrett, Wendy Burke, D Pietersma, Melissa K. Stuart, Ugochi Emeribe, Epie Boven
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Mathias Bressel, Rhonda Huynh, Patricia Banks, Roslyn Wallace, Anis Hamid, Andrisha Jade Inderjeeth, Ben Tran, Arun Azad, Ramin Alipour, Grace Kong, Aravind Ravi Kumar, Javad Saghebi, Scott Williams, Timothy Akhurst, Rodney J. Hicks, Michael S. Hofman
Vânia T. M. Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gábor Mikala, Tamás Masszi, Li J, Marcelo Capra, Ângelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Löw, Morio Matsumoto, Mary Li, Neal Sule, Margaret Polinkovsky, Randy Davis, Shelley Bright, Astrid McKeown, Joanna Opalińska, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.